News
PBM
0.8795
-5.43%
-0.0505
Weekly Report: what happened at PBM last week (1222-1226)?
Weekly Report · 16h ago
Weekly Report: what happened at PBM last week (1215-1219)?
Weekly Report · 12/22 10:26
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 12/19 17:05
Market-Moving News for December 19th
Benzinga · 12/19 12:21
Psyence Biomedical announces approval for use of PsyLab’s psilocybin product
TipRanks · 12/19 12:15
Psyence BioMed Wins Ethics Approval for PsyLabs Psilocybin in Phase IIb Cancer Trial
Reuters · 12/19 12:00
PSYENCE BIOMED ANNOUNCES APPROVAL FOR USE OF PSYLABS’ PSILOCYBIN PRODUCT IN PHASE IIB CLINICAL TRIAL
Reuters · 12/19 12:00
PSYENCE BIOMEDICAL LTD: STUDY REMAINS ON TRACK TO DELIVER TOP-LINE RESULTS IN 2026
Reuters · 12/19 12:00
Weekly Report: what happened at PBM last week (1208-1212)?
Weekly Report · 12/15 10:33
Psyence Biomedical CEO says 2025 was a ‘turning point’ for company
TipRanks · 12/09 12:26
Psyence BioMed Reports Phase IIb Trial Progress and Strengthened Cash Position
Reuters · 12/09 12:02
Weekly Report: what happened at PBM last week (1201-1205)?
Weekly Report · 12/08 10:32
Weekly Report: what happened at PBM last week (1124-1128)?
Weekly Report · 12/01 10:27
Psyence Biomedical announces psilocybin longevity research program
TipRanks · 11/25 12:15
Psyence BioMed Launches Psilocybin Longevity Research Program
Reuters · 11/25 12:11
Weekly Report: what happened at PBM last week (1117-1121)?
Weekly Report · 11/24 10:32
Psyence BioMed Expands Ibogaine Operations in Africa with Strategic Investment
TipRanks · 11/21 22:53
Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations
Reuters · 11/21 22:18
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/21 12:05
Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 11/21 09:41
More
Webull provides a variety of real-time PBM stock news. You can receive the latest news about Psyence Biomedical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.